The medroxyprogesterone (Depo-Provera) injection has a black box warning due to:

Medroxyprogesterone (Depo-Provera) is a long-acting injectable contraceptive that suppresses ovulation by inhibiting the hypothalamic-pituitary-ovarian axis. It is highly effective and convenient because it requires administration only every three months. However, its prolonged use has been associated with significant effects on bone metabolism, especially in adolescents and young adults. This risk is highlighted in its boxed warning and requires patient counseling and monitoring. Rationale: A. Increased risk of strokes is more commonly associated with estrogen-containing contraceptives rather than progestin-only methods like Medroxyprogesterone (Depo-Provera). While any hormonal therapy may carry some vascular risk depending on patient factors, stroke risk is not the primary boxed warning for this medication. B. Decreased bone mineral density is the black box warning associated with Medroxyprogesterone (Depo-Provera). Prolonged use suppresses estrogen levels, which can lead to reduced bone formation and increased bone resorption. This effect is particularly concerning in adolescents and young adults, and long-term use requires careful risk-benefit assessment and counseling on bone health. C. Stevens-Johnson syndrome is not associated with Medroxyprogesterone (Depo-Provera). Severe cutaneous hypersensitivity reactions are not a known boxed warning for this medication. SJS is more commonly associated with certain anticonvulsants and antibiotics rather than hormonal contraceptives. D. Significant hypertension is not a recognized black box warning or primary adverse effect of Medroxyprogesterone (Depo-Provera). Unlike estrogen-containing contraceptives, progestin-only injections have a lower impact on blood pressure regulation. While monitoring is still important in hypertensive patients, it is not the primary boxed warning concern.